We are live on ! Find out more

SGYP

Synergy Pharmaceuticals, Inc Common Stock

SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

143 hedge funds and large institutions have $436M invested in Synergy Pharmaceuticals, Inc Common Stock in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 60 increasing their positions, 32 reducing their positions, and 19 closing their positions.

New

Increased

Maintained

Reduced

Closed

88% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 32

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

2% less funds holding

Funds holding: 146 → 143 (-3)

39% less capital invested

Capital invested by funds: $717M → $436M (-$281M)

74% less call options, than puts

Call options by funds: $2M | Put options by funds: $7.67M

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders

143

Holders Change

-3

Holders Change %

-2.05%

% of All Funds

3.57%

Holding in Top 10

–

Holding in Top 10 Change

-2

Holding in Top 10 Change %

-100%

% of All Funds

–

New

Increased

Reduced

Closed

Calls

$2M

Puts

$7.67M

Net Calls

-$5.67M

Net Calls Change

-$4.62M

Top Buyers

Rank	Fund	Capital Flow
1	UBS Group Zurich, Switzerland	+$5.71M
2	JP Morgan Chase New York	+$4.83M
3	Balyasny Asset Management Chicago, Illinois	+$4.72M
4	Deutsche Bank Frankfurt Am Main Ge, Germany	+$4.56M
5	Goldman Sachs New York	+$3.79M

Top Sellers

Rank	Fund	Capital Flow
1	O OrbiMed New York	-$25.7M
2	TCP Tourbillon Capital Partners New York	-$18.5M
3	Millennium Management New York	-$13.6M
4	GPP Great Point Partners Greenwich, Connecticut	-$13.5M
5	TCM TimesSquare Capital Management New York	-$11.4M

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	26 Charles Schwab San Francisco, California	$2.74M	-$121K	-35,368	-4%
27	27 HighTower Advisors Chicago, Illinois	$2.44M	+$139K	+40,758	+5%
28	KCM 28 Kingdon Capital Management New York	$2.23M	-$701K	-205,483	-21%
29	AI 29 Axiom Investors Greenwich, Connecticut	$2.21M	-$568K	-166,417	-18%
30	30 AllianceBernstein Nashville, Tennessee	$1.96M	+$1.14M	+335,000	+99%
31	CCMU 31 Cheyne Capital Management (UK) London, United Kingdom	$1.88M	+$1.74M	+511,500	+365%
32	32 Allianz Asset Management Munich, Germany	$1.61M	-$13.8K	-4,036	-0.7%
33	ARTA 33 A.R.T. Advisors New York	$1.39M	+$1.63M	+479,300	New
34	TA 34 Teachers Advisors New York	$1.22M	+$47.7K	+13,971	+3%
35	35 Swiss National Bank Zurich, Switzerland	$1.08M	–	–	–
36	36 California State Teachers Retirement System (CalSTRS) West Sacramento, California	$1.06M	-$125K	-36,585	-9%
37	TMC 37 Trellus Management Company Delray Beach, Florida	$1.05M	+$59.7K	+17,500	+5%
38	PPA 38 Parametric Portfolio Associates Seattle, Washington	$1.03M	+$185K	+54,262	+18%
39	CS 39 Credit Suisse Zurich, Switzerland	$1M	-$193K	-56,616	-14%
40	NFA 40 Nationwide Fund Advisors Columbus, Ohio	$955K	+$56.4K	+16,542	+5%
41	CHAM 41 Clear Harbor Asset Management Stamford, Connecticut	$880K	+$1.36K	+400	+0.1%
42	ACM 42 Asymmetry Capital Management San Francisco, California	$786K	-$347K	-101,592	-27%
43	43 RhumbLine Advisers Boston, Massachusetts	$752K	+$11.9K	+3,490	+1%
44	VEA 44 Virtus ETF Advisers New York	$716K	–	–	–
45	MCM 45 Moore Capital Management New York	$653K	–	–	–
46	46 New York State Common Retirement Fund Albany, New York	$640K	–	–	–
47	47 Wells Fargo San Francisco, California	$638K	+$115K	+33,802	+18%
48	48 Jane Street New York	$571K	+$573K	+167,985	+579%
49	CCMH 49 Cornerstone Capital Management Holdings New York	$562K	+$209K	+61,200	+46%
50	50 Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada	$508K	+$1.26K	+371	+0.2%

SGYP Hedge Fund Activity: Q3 2017 in Review

143 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q3 2017, worth a combined $436M — down 39% from $717M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of SGYP and 18 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 60 added.

The largest buyer was UBS Group, adding an estimated $5.71M. The largest seller was OrbiMed, cutting an estimated $25.7M.

143 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q3 2017, down from 146 in Q2 2017.
Funds reported $436M of Synergy Pharmaceuticals, Inc Common Stock stock for Q3 2017, down 39% quarter-over-quarter.
18 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q3 2017 and 19 closed out, a net change of -1 holder.
The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q3 2017 was UBS Group, an estimated $5.71M added.
The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q3 2017 was OrbiMed, an estimated $25.7M sold.

Based on aggregated 13F filings for Q3 2017.

Synergy Pharmaceuticals, Inc Common Stock SGYP